Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies
Authors:
- Daniël F. OssesDODaniël F. Osses
- Christian ArsovCAChristian Arsov
- Lars SchimmöllerLSLars Schimmöller
- Ivo G. SchootsISIvo G. Schoots
- Geert J.L.H. van LeendersGLGeert J.L.H. van Leenders
- Irene EspositoIrene Esposito
- Sebastiaan RemmersSRSebastiaan Remmers
- Peter AlbersPAPeter Albers
- Monique J. RoobolMonique J. Roobol
Open Access
- 10 December 2020
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 10 (4) , 270
Abstract
We aimed to investigate the relation between largest lesion diameter, prostate-specific antigen density (PSA-D), age, and the detection of clinically significant prostate cancer (csPCa) using first-time targeted biopsy (TBx) in men with Prostate Imaging—Reporting and Data System (PI-RADS) 3 index lesions. A total of 292 men (2013–2019) from two referral centers were included. A multivariable logistic regression analysis was performed. The discrimination and clinical utility of the built model was assessed by the area under the receiver operation curve (AUC) and decision curve analysis, respectively. A higher PSA-D and higher age were significantly related to a higher risk of detecting csPCa, while the largest index lesion diameter was not. The discrimination of the model was 0.80 (95% CI 0.73–0.87). When compared to a biopsy-all strategy, decision curve analysis showed a higher net benefit at threshold probabilities of ≥2%. Accepting a missing ≤5% of csPCa diagnoses, a risk-based approach would result in 34% of TBx sessions and 23% of low-risk PCa diagnoses being avoided. In men with PI-RADS 3 index lesions scheduled for first-time TBx, the balance between the number of TBx sessions, the detection of low-risk PCa, and the detection of csPCa does not warrant a biopsy-all strategy. To minimize the risk of missing the diagnosis of csPCa but acknowledging the need of avoiding unnecessary TBx sessions and overdiagnosis, a risk-based approach is advisable.Keywords
This publication has 39 references indexed in Scilit:
- Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validationEuropean Radiology, 2020
- Personalized strategies in population screening for prostate cancerInternational Journal of Cancer, 2020
- Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology Focus, 2020
- PI‐RADS: Past, present, and futureJournal of Magnetic Resonance Imaging, 2019
- Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standardEuropean Journal of Radiology, 2019
- Direct comparison of PI-RADS version 2 and version 1 regarding interreader agreement and diagnostic accuracy for the detection of clinically significant prostate cancerEuropean Journal of Radiology, 2017
- Evaluation of MRI for diagnosis of extraprostatic extension in prostate cancerJournal of Magnetic Resonance Imaging, 2017
- Head-to-head comparison of PI-RADS v2 and PI-RADS v1European Journal of Radiology, 2016
- Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of referenceEuropean Radiology, 2015
- ESUR prostate MR guidelines 2012European Radiology, 2012